Number To Know…5,000,000
Executive Summary
$5m is how much Novo Nordisk has invested in bionic pancreas developer, Beta Bionics.
$5m is the amount of cash Novo Nordisk has pumped into Beta Bionics as part of a strategic partnership between the two companies to develop a bionic pancreas that will be compatible with the drug maker’s NovoLog insulins. Beta’s iLet bionic pancreas is designed for automated delivery of insulin alone and insulin and glucagon, and incorporates Dexcom’s continuous glucose monitoring technology and smart algorithm). Beta last year also received a $5m investment from another major insulin drug maker, Eli Lilly.
Meddevicetracker subscribers – click here to get a profile of Beta Bionics and data on iLet.
Not a subscriber? Click here to request your free demo today.